Last reviewed · How we verify
Vaccination with ACAM2000
At a glance
| Generic name | Vaccination with ACAM2000 |
|---|---|
| Sponsor | Emergent BioSolutions |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
- MVA Post-Event: Administration Timing and Boost Study (PHASE1, PHASE2)
- Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia (PHASE3)
- Break-through Infection Following Mpox vaccinatIon
- Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults (PHASE2)
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |